28L Stock Overview
A pharmaceutical company, researches, develops, and sells medical treatments and lifestyle products in the field of women's health.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
PEPTONIC medical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0002 |
| 52 Week High | SEK 0.005 |
| 52 Week Low | SEK 0.0002 |
| Beta | 0.40 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -95.00% |
| 33 Year Change | -99.71% |
| 5 Year Change | n/a |
| Change since IPO | -99.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 28L | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.7% | -1.8% |
| 1Y | -95.0% | -12.7% | 13.2% |
Return vs Industry: 28L underperformed the German Pharmaceuticals industry which returned -11.4% over the past year.
Return vs Market: 28L underperformed the German Market which returned 16.1% over the past year.
Price Volatility
| 28L volatility | |
|---|---|
| 28L Average Weekly Movement | 0% |
| Pharmaceuticals Industry Average Movement | 7.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine 28L's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 26 | Anna Linton | www.peptonicmedical.se |
PEPTONIC medical AB (publ), a pharmaceutical company, researches, develops, and sells medical treatments and lifestyle products in the field of women's health. It offers VagiVital, a hormone-free treatment for symptoms related to vaginal atrophy, such as pain during intercourse, burning, itching, and dryness, as well as moisturizing and an oil-based intimate wash. The company also provides lifestyle consumer products under the Lunette brand.
PEPTONIC medical AB (publ) Fundamentals Summary
| 28L fundamental statistics | |
|---|---|
| Market cap | €29.65m |
| Earnings (TTM) | -€49.28m |
| Revenue (TTM) | €33.23m |
0.0x
P/S Ratio0.0x
P/E RatioIs 28L overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 28L income statement (TTM) | |
|---|---|
| Revenue | SEK 33.23m |
| Cost of Revenue | SEK 19.29m |
| Gross Profit | SEK 13.94m |
| Other Expenses | SEK 63.22m |
| Earnings | -SEK 49.28m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 06, 2024
| Earnings per share (EPS) | -0.0086 |
| Gross Margin | 41.95% |
| Net Profit Margin | -148.28% |
| Debt/Equity Ratio | 14.3% |
How did 28L perform over the long term?
See historical performance and comparison